HomeInvestor Relations

Investor Relations

Investor Home

Corporate Profile

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate... More

Stock Quote

MNOV (Common)
ExchangeNASDAQ (US Dollar)
Price$2.11
Change (%) Stock is Down 0.04 (1.86%)
Volume103,322
Data as of 03/07/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

2012 Annual Report

Recent News

More
DateTitle 
01/14/14MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S.Printer Friendly Version
11/11/13MediciNova Receives New Patent Covering MN-221 in Irritable Bowel SyndromePrinter Friendly Version
11/07/13MediciNova Reports Third Quarter 2013 ResultsPrinter Friendly Version
10/16/13MediciNova Appoints Yutaka Kobayashi to Its Board of DirectorsPrinter Friendly Version

Upcoming Events

More
There are currently no events scheduled.

What's New

There are currently no items available.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Medicinova Inc posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Recent News